Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parabilis MedicinesPBLS -7.41%10 Debt-to-Equity is -3.55 as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Parabilis Medicines ranks worse than 103519.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Parabilis Medicines's Debt-to-Equity or its related term are showing as below:
PBLS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.55 Med: -1.19 Max: 1.17
Current: -3.55
During the past 2 years, the highest Debt-to-Equity Ratio of Parabilis Medicines was 1.17. The lowest was -3.55. And the median was -1.19.
PBLS's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs PBLS: -3.55
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Parabilis Medicines Debt-to-Equity Related Terms
Parabilis Medicines Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Debt-to-Equity Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
Debt-to-Equity
1.17
-3.55
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
Debt-to-Equity
1.17
-3.55
PBLS vs IDYA, ELVN, BEAM: Debt-to-Equity Comparison
For the Biotechnology subindustry, Parabilis Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a Debt-to-Equity of -3.55 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #999999 out of 966 companies in the Biotechnology industry.
Is Parabilis Medicines' Debt-to-Equity too high?
Parabilis Medicines' current Debt-to-Equity is -3.55. Based on the distribution chart, Parabilis Medicines ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Debt-to-Equity compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #999999 out of 966 companies for Debt-to-Equity. This places Parabilis Medicines in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Parabilis Medicines and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parabilis Medicines's current Debt-to-Equity is -3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Debt-to-Equity of -3.55. The current Debt-to-Equity is -3.55. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Debt-to-Equity is -3.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
